In recent years, immune checkpoint inhibitors (ICIs), represented by programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) monoclonal antibodies, have revolutionized the treatment of malignant tumors. This evidence concerns the gene CD274 and cancer.